Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: Results of a single center in Central Anatolia

By Altinbas Mustafa   Er Ozlem   Ozkan Metin   Coskun Hasan   Gulmez Inci   Ekici Eyup   Kaplan Bunyamin   Eser Bulent   Ozesmi Mustafa  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 359-366

Humana Press, Inc

Access to resources Recommend Favorite

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon- after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

By Atzpodien J.   Lopez Hanninen E.   Kirchner H.   Franzke A.   Korfer A.   Volkenandt M.   Duensing S.   Schomburg A.   Chaitchik S.   Poliwoda H.  

European Journal of Cancer, Vol. 31, Iss. 6, 1995-06 ,pp. : 876-881

Elsevier

Access to resources Recommend Favorite

Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs

By Fjällskog M.-L.   Sundin A.   Westlin J.-E.   Öberg K.   Janson E.   Eriksson B.  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 35-42

Humana Press, Inc

Access to resources Recommend Favorite

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer

By Polee M.B.   Verweij J.   Siersema P.D.   Tilanus H.W.   Splinter T.A.W.   Stoter G.   Van der Gaast A.  

European Journal of Cancer, Vol. 38, Iss. 11, 2002-07 ,pp. : 1495-1500

Elsevier

Access to resources Recommend Favorite

Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors

By Ku Geoffrey   O'Reilly Eileen   Saltz Leonard   Schrag Deborah   Maki Robert   Kelsen David   Ilson David  

Cancer Investigation, Vol. 27, Iss. 4, 2009-05 ,pp. : 402-406

Informa Healthcare

Access to resources Recommend Favorite